The Power of the Pharmaceutical Companies

This documentary examines the economic and ethical considerations surrounding the pharmaceutical industry, focusing on the pricing and development of innovative medical treatments. It investigates the financial structures and decision-making processes that influence the cost of new drugs, particularly in the context of life-saving therapies.

The program specifically analyzes Kymriah, a gene therapy approved in Europe in 2018 for cancer treatment. It details the therapy’s mechanism, its reported efficacy over an 18-month period, and its cost of 370,000 Swiss francs per patient. The documentary traces Kymriah’s origins from university research, funded by public money and donations, to its acquisition and commercialization by Novartis. It highlights a trend where pharmaceutical companies often act as capital providers, collaborating with academic institutions or acquiring smaller biotech firms to bring new drugs to market. The narrative also addresses the industry’s evolving justification for high drug prices, shifting from research costs to the value of extended patient life.

Key Themes & Topics Examined

• The development and commercialization of high-cost pharmaceutical therapies.
• The financial models and pricing strategies within the pharmaceutical industry.
• The role of public funding and university research in drug discovery.
• The relationship between pharmaceutical companies, academic institutions, and biotech firms.
• The debate surrounding drug pricing, insurance coverage, and market transparency.
• The ethical implications of valuing human life in the context of medical treatment costs.

Archival & Investigative Sources

• Case study of Kymriah gene therapy.
• Analysis of pharmaceutical company practices, including Novartis.
• Interviews and perspectives on drug development and pricing.
• Data on the origins of newly approved medicines in the US.

Frequently Asked Questions

What is Kymriah?

Kymriah is a gene therapy approved in Europe in 2018. It involves genetically reprogramming a patient’s immune cells into cancer killer cells and reinfusing them to treat certain cancers.

How much does Kymriah cost?

Kymriah costs 370,000 Swiss francs per patient, leading to discussions regarding insurance coverage and affordability.

Who developed Kymriah?

The initial research for Kymriah was conducted at a US university by Professor Carl June, with funding from tax money and donations. Novartis later acquired exclusive marketing rights and funded the necessary clinical trials for its market launch.

How do pharmaceutical companies justify high drug prices?

Historically, high drug prices were justified by research costs. More recently, the industry has begun to argue for prices based on the value of the gained lifetime for patients.